Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two upcoming virtual conferences: the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 10:15 am ET and the Chardan 5th Annual Manufacturing Summit on April 26, 2021, at 1:00 pm ET. Both events will feature fireside chats led by key executives, including the President and CEO, RA Session II, along with others from the company.

Webcasts of these events can be accessed on the Taysha corporate website, with archived versions available for 60 days.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the 20^th Annual Needham Virtual Healthcare Conference and the Chardan 5^th Annual Manufacturing Summit.

Conferences Details:
Event:		20th Annual Needham Virtual Healthcare Conference
Date:		Monday, April 12, 2021
Time:		10:15 am ET
Format:		Fireside chat
Participants:		RA Session II, President, Founder and CEO
Event:		Chardan 5th Annual Manufacturing Summit
Date:		Monday, April 26, 2021
Time:		1:00 pm ET
Format:		Fireside chat
Participants:		RA Session II, President, Founder and CEO
		Fred Porter, Ph.D., Chief Technical Officer
		Greg Gara, Senior Vice President of Manufacturing

Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005218/en/

FAQ

What is Taysha Gene Therapies' participation in the Needham Virtual Healthcare Conference?

Taysha Gene Therapies will participate in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 10:15 am ET.

When will Taysha Gene Therapies appear at the Chardan Manufacturing Summit?

Taysha Gene Therapies will participate in the Chardan 5th Annual Manufacturing Summit on April 26, 2021, at 1:00 pm ET.

Who will represent Taysha Gene Therapies at the virtual conferences?

RA Session II, President and CEO, along with other key executives including Fred Porter, Ph.D., and Greg Gara, will represent Taysha Gene Therapies.

How can I access the webcasts for Taysha Gene Therapies' conferences?

Webcasts for both conferences will be available in the 'Events & Media' section of the Taysha corporate website.

What is the focus of Taysha Gene Therapies?

Taysha Gene Therapies focuses on developing AAV-based gene therapies for treating monogenic diseases of the central nervous system.